-
Immutep Quarterly Activities Report
30 Jan 2023 13:00 GMT
… 1st line non-small cell lung cancer (1L NSCLC)
Compelling Phase II … a chemotherapy agent which is oxaliplatin, carboplatin, or topotecan. They follow …
-
Synthesis of Gingerol-Metals Complex and in-vitro Cytotoxic Activity on Human Colon Cancer Cell Line
27 Jan 2023 13:06 GMT
… or derivatives like carboplatin or oxaliplatin are used to treat around … pancreatic cancer cell PANC-1, lung cancer cells H1299 and breast cancer …
-
Transferrin-Modified Mangiferin-Loaded SLNs: Preparation, Characterization, and Application in A549 Lung Cancer Cell
08 Jun 2022 09:43 GMT
… chemotherapeutic drugs (such as oxaliplatin, adriamycin, 5-fluorouracil, … .
Biodistribution Study
A549 lung cancer cells were implanted in … effect of quercetin in lung cancer therapy. Int J Nanomedicine … using gold nanorods for lung cancer therapy. Int J …
-
Three-Year Data from Phase 3 CheckMate -9LA Trial Demonstrate Long-Term, Durable Survival Outcomes of Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer
06 Jun 2022 11:06 GMT
… to biomarkers.
About Lung Cancer
Lung cancer is the leading cause … positive) non-small cell lung cancer (NSCLC).
OPDIVO® (nivolumab … treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. This … non-small cell lung cancer; Checkmate 743–previously …
-
Landmark Five-Year Data from Phase 3 CheckMate -227 Trial Demonstrate Long-Term, Durable Survival Outcomes with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
06 Jun 2022 11:06 GMT
… immunotherapy combination in metastatic lung cancer and melanoma, and … L1 ≥1%.
About Lung Cancer
Lung cancer is the leading cause … treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. This … squamous non-small cell lung cancer; Checkmate 743–previously …
-
Neoadjuvant Opdivo (nivolumab) with Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial
11 Apr 2022 15:15 GMT
… of four tumor types: lung cancer, bladder cancer, esophageal… distant metastases.
About Lung Cancer
Lung cancer is the leading cause … treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. This … non-small cell lung cancer; Checkmate 743–previously …
-
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
29 Mar 2022 10:59 GMT
… distant metastases.
About Lung Cancer
Lung cancer is the leading cause … positive) non-small cell lung cancer (NSCLC).
OPDIVO® (nivolumab … treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. This … non-small cell lung cancer; Checkmate 743–previously …
-
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
28 Feb 2022 11:59 GMT
… of four tumor types: lung cancer, bladder cancer, esophageal… distant metastases.
About Lung Cancer
Lung cancer is the leading cause … treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. This … non-small cell lung cancer; Checkmate 743–previously …
-
Neoadjuvant Opdivo (nivolumab) Plus Chemotherapy Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -816 Trial
08 Nov 2021 11:59 GMT
… of four tumor types: lung cancer, bladder cancer, esophageal… distant metastases.
About Lung Cancer
Lung cancer is the leading cause … treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. This … non-small cell lung cancer; Checkmate 743–previously …
-
Longest Overall Survival Ever Seen in Advanced Gastric Cancer
20 Jan 2023 14:56 GMT
… (leucovorin), fluorouracil (5-FU), and oxaliplatin (OX).
"Zolbetuximab plus mFOLFOX6 … tumors, and biliary, ovarian, and lung cancers.
In a discussion of the …
About
© 1995-2023